Exploratory analyses of incidence of skin rash and efficacy with apalutamide (APA) treatment of patients (pts) with advanced prostate cancer in SPARTAN and TITAN studies

SunRISe-2: a phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder

SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy

IMvigor130

Maintenance after disease control with platinum-based chemotherapy: The JAVELIN Bladder 100 study

Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

Patient-reported pain by clinical outcome in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study

Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

Clinical trial protocol for PSMA-SELECT: Dutch National Randomized study of PSMA-PET/CT as a triage tool for pelvic lymph node dissection in prostatectomy patients

3D virtual and printed reconstructions of renal cell cancer with venous thrombus extension for surgical planning. Phase III NCT03738488

A phase 2 study of intrapleural instillation of the nivolumab in cancer patients with pleural effusion

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

A phase 3, randomized, double-blind trial of nivolumab or nivolumab plus ipilimumab versus placebo in patients with localized renal cell carcinoma who underwent radical or partial nephrectomy and are at high risk of relapse (CheckMate 914)

Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the ‘NIMBUS’ phase III clinical trial